Lovastatin

證據等級: L5

預測適應症: 6 個

Lovastatin: From Hypercholesterolemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Lovastatin is a first-generation HMG-CoA reductase inhibitor (statin), historically used to lower LDL cholesterol in primary hypercholesterolemia. The TxGNN model predicts it may also be effective for Homozygous Familial Hypercholesterolemia (HoFH), but the supporting evidence base is thin: 3 clinical trials (none testing lovastatin itself) and 19 publications, several of which report that lovastatin has limited or no effect in the receptor-negative HoFH subtype.

Quick Overview

Item	Content
Original Indication	Primary hypercholesterolemia (well-established statin class indication; no formal license record is present in this evidence pack)
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.89%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Research Question (data-driven decision stage S1 — insufficient to move toward Go)

Why is This Prediction Reasonable?

Detailed mechanism-of-action documentation for this candidate is not available in the evidence pack (flagged as a High-severity data gap). Based on general pharmacology and the mechanistic notes accompanying this evidence pack, lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. This reduces intracellular cholesterol, which in turn upregulates LDL-receptor expression on hepatocytes and accelerates clearance of circulating LDL particles — the core mechanism behind lovastatin’s established efficacy in hypercholesterolemia.

The link to HoFH is mechanistically plausible on the surface, since HoFH is characterized by extremely elevated LDL-cholesterol. However, the evidence pack’s own repurposing rationale flags an important limitation: lovastatin’s efficacy depends on the presence of functional LDL receptors, and HoFH patients typically carry two defective or absent LDLR alleles. The literature bears this out — receptor-negative HoFH patients show no meaningful LDL-cholesterol reduction on lovastatin, while receptor-defective (partial-function) patients may see a modest, genotype-dependent benefit, likely via reduced hepatic VLDL secretion rather than enhanced LDL clearance.

This means the prediction is directionally reasonable but clinically narrow: any real-world utility would be confined to a genetically defined HoFH subgroup, and would almost certainly require adjunctive therapy (apheresis, bile-acid sequestrants, or newer agents such as PCSK9 inhibitors) rather than lovastatin monotherapy.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03884452	Phase 3	Completed	50	Tested ezetimibe 10 mg added to background atorvastatin or simvastatin in HoFH — not a lovastatin trial; relevant only as background statin-class context
NCT03885921	Phase 3	Completed	44	Long-term (24-month) open-label extension evaluating ezetimibe safety/tolerability on top of atorvastatin/simvastatin in HoFH; again, not lovastatin-specific
NCT03510715	Phase 3	Completed	18	Evaluated alirocumab (a PCSK9-targeting monoclonal antibody) in pediatric/adolescent HoFH — a mechanistically distinct drug class from statins

Note: None of the identified trials directly test lovastatin in HoFH; all three test other agents (ezetimibe, alirocumab) added to statin background therapy.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3397806	1988	Cohort	The Journal of Pediatrics	Lovastatin (2 mg/kg/day) in 3 children with receptor-negative HoFH produced no reduction in LDL-cholesterol or LDL turnover — direct negative evidence for the receptor-negative subtype
3534334	1986	Case Report	JAMA	A child with HoFH who underwent liver transplantation (restoring ~60% LDL-receptor activity) achieved normal cholesterol levels; lovastatin’s role was adjunctive
1785747	1991	Cohort	Anales Españoles de Pediatría	Two HoFH patients treated with lovastatin plus probucol/cholestyramine; response linked to LDL-receptor analysis findings
2209665	1990	Case report	European Journal of Pediatrics	Single HoFH patient on weekly LDL-apheresis (HELP) with lovastatin as adjunct; long-term tolerability and xanthoma regression noted
8637439	1996	Case/family study	Metabolism	Compared lovastatin and cholestyramine effects on plasma sterols in a homozygous sitosterolemia patient with concomitant FH and her heterozygous father
29284604	2018	Cohort	Arteriosclerosis, Thrombosis, and Vascular Biology	Shows HoFH patients with identical LDLR mutations vary in receptor expression, explaining variable drug response — supports genotype-dependence relevant to statin efficacy generally
12034651	2002	RCT	Circulation	Multicenter, double-blind RCT of ezetimibe added to atorvastatin/simvastatin in 50 HoFH patients — background-statin context, not lovastatin itself
7229037	1981	Mechanistic (in vitro)	The Journal of Clinical Investigation	Fibroblast studies of compactin (ML-236B, an early statin) characterizing LDL-receptor binding/degradation defects across HoFH genotypes — foundational mechanism work, not lovastatin itself
14727947	2003	Review	American Journal of Cardiovascular Drugs	General pharmacology review of ezetimibe as a cholesterol-absorption inhibitor; background context only
10146648	1993	Cohort	Transfusion Science	Two girls with FH treated 7 years with plasma exchange/LDL-apheresis, some periods combined with simvastatin (not lovastatin)

US Market Information

Lovastatin currently has no license records in this evidence pack — market status is “Not Marketed” with 0 registered authorizations.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Research Question (Hold pending targeted data)

Rationale: The mechanistic story is plausible in general terms, but the disease-specific literature actively undercuts it: lovastatin shows no effect in receptor-negative HoFH (the more common and severe genotype) and only a limited, genotype-dependent effect in receptor-defective HoFH. No trial in the evidence pack tests lovastatin itself in this indication — all identified trials study ezetimibe or alirocumab against a statin background. Evidence level L3 (observational/case-level only) is not sufficient to support progression toward Go.

To proceed, the following is needed:

TFDA/regulatory label data (warnings, contraindications) — currently blocking, required before any S1 safety pre-assessment
Confirmed mechanism-of-action documentation from DrugBank
LDL-receptor genotype stratification data (receptor-negative vs. receptor-defective) to define which HoFH subpopulation, if any, could plausibly benefit
A trial or registry dataset testing lovastatin specifically (not ezetimibe/alirocumab as statin add-ons) in HoFH

Context note: within the same evidence pack, the model’s rank-2 prediction (“hyperlipoproteinemia,” L1 evidence, decision stage S3) is markedly stronger — but per its own rationale, that indication largely overlaps with lovastatin’s already-approved use and is not true repurposing.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.